TCF21 and invasive ductal breast carcinoma: As shown in Table 2, stratified analyses based on pathological type indicated that TCF21 rs12190287 polymorphism was only associated with the reduced risk of infiltrative ductal carcinoma (G vs. C, OR = 0.78, 95%CI = 0.68-0.89, P < 0.001; GG vs. CC, OR = 0.59, 95%CI = 0.45-0.79, P < 0.001; CG vs. CC, OR = 0.82, 95%CI = 0.67-0.99, P = 0.04; GG + CG vs. CC, OR = 0.76, 95%CI = 0.83-0.91, P = 0.003; GG vs. CG + CC, OR = 0.67, 95%CI = 0.51-0.86, P = 0.002).